Cardiac troponin T (cTnT) and B-type natriuretic peptide (BNP) have been used to estimate prognosis in heart failure. However, most studies have evaluated decompensated patients using single measurements. To determine the value of serial measurements, we evaluated 190 stable chronic heart failure patients every 3 months during 2 years. Elevations of cTnT (>0.03 ng/mU or BNP detected at any time during clinical follow-up in ambulatory patients are highly associated with an increased risk of death, cardiac transplantation, and/or hospitalization. Combined elevations defined the highest risk group. The ability to monitor changes by serial measurements adds to the assessment of risk.
|Original language||English (US)|
|Number of pages||6|
|State||Published - Mar 1 2008|
ASJC Scopus subject areas
- Cardiology and Cardiovascular Medicine